# C-BIOMEX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/c-biomex

- Industry: Biotechnology
- Headquarters: South Korea
- Website: https://cbiomex.com/
- Total disclosed funding: $7.5M
- Latest round: Series B (Jun 22, 2022)
- Investors on record: 8

## About

Based in Gyeongsangbuk-do, South Korea, and founded in 2017, Cbiomex Inc. also known as C-BIOMEX operates as a biopharmaceutical company that is focused on the development of peptide therapeutics. In June 2022, the firm raised KRW 6.5 billion in series B funding led by investors E&Venture Partners, Enlight Ventures, Mirae Asset Venture Investment, and Stassets Investment. Along with the participation of Innopolis Partners and SHIN POONG PHARM. CO., LTD. The firm as of April 2023, is led by its CEO, Cha Junhoe.

The company develops theragnostic technology for peptide radioactive treatment and diagnosis for cancer. Through its platform, CUS™, the company is working on radioactive isotopes for cancer cells, based on preclinical data to screen peptides that selectively bind to target substances. Their peptides are designed to have higher stability in blood and greater binding ability and selectivity to target substances, making them more effective than existing drugs. The projects in C-Biomex’s pipeline, as of April 2023, are CBT-001, for kidney cancer, is in late discovery, and CBT-002, for neuroendocrine tumor, CBT-004, for solid cancer, and CBT-005, for achondroplasia, are in early discovery stage.

The company plans to its June 2022 funding to launch the phase 1 clinical IND of CBT-001.

## Funding rounds

- Series B, Jun 22, 2022, $5M — Innopolis Partners, Mirae Asset Venture Investment, Enlight Ventures, E&Venture Partners, Stassets Investment, SHIN POONG PHARM. CO.,LTD
- Series A, Mar 26, 2020, $2.5M — Innopolis Partners, Smilegate Investment
- Seed, May 1, 2018 — POSTECH Holdings

## Investors

- POSTECH Holdings (https://capitalatlas.ai/funds/postech-holdings) — Seed
- Innopolis Partners (https://capitalatlas.ai/funds/innopolis-partners) — Series A, Series B
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series A
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series B
- Enlight Ventures (https://capitalatlas.ai/funds/enlight-ventures) — Series B
- E&Venture Partners (https://capitalatlas.ai/funds/e-venture-partners) — Series B
- Stassets Investment (https://capitalatlas.ai/funds/stassets-investment) — Series B
- SHIN POONG PHARM. CO.,LTD — Series B